About Sequencebase
Sequencebase is a Healthcare company based in Edison (United States) founded in 2006, and was acquired by Clarivate in September 2019. It operates as a biological sequences from global patents are accessed through curated databases. It operates in the Healthcare and Technology sectors. The company was acqui-hired. Its focus areas include Life Sciences, Genomics, Genome Informatics and Integrative Bioinformatics Platforms. Its legal entity is SequenceBase Corporation. Its competitors include Human Longevity, Helix, Benchling, Genuity Science and Inpharmatica and 4 more; 8 of its 9 listed competitors have raised funding.
Company details
SequenceBase is an international patent sequence information provider. It develops and markets the SequenceBase Research Portal which is the definitive web-based access point for comprehensive patent sequence searching, featuring streamlined, non-redundant versions of USGENE, GENESEQ, and GENESEQ FASTAlert databases. Databases offered include GENESEQ - which covers all biological sequences patented since 1981 from 52 worldwide patent-issuing authorities including WO, US, EP, JP, DE, IN, KR, and CN and is manually curated and professionally annotated; USGENE which has a thorough coverage of biological sequences from U.S. patents and published patent applications; and WOGENE which claims to have a thorough coverage of biological sequences from international published patent applications. It claims to have a through coverage for all its databases.
- Headquarters Edison, United States
- Stage Acquired
- SectorsHealthcareTechnology
- Website sequencebase.com
- Social LinkedIn X
- Acquired by Clarivate (Sep 2019)
- Legal Name Sequencebase Corporation
Investors in Sequencebase
Sequencebase has secured backing from 1 investor. Prominent investors backing the company include Clarivate.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Research, data, and intellectual property solutions are provided globally. | 2016 | clarivate.com | Philadelphia, United States |
Investor details for Sequencebase
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Sequencebase
2 dated milestones of Sequencebase across 13 years, from founding to its latest funding, stage changes and deals.
- Founded Sequencebase is founded.
- Exit Acquired by Clarivate.
Competitors of Sequencebase
Sequencebase has 9 listed competitors in our database, 8 of them funded. They include Human Longevity, Helix, Benchling, Genuity Science and Inpharmatica, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| humanlongevity.com | 2013 | San Diego, United States | $376.72M | 83 | Genomics data and cell therapy-based diagnostic and therapeutic solutions | |
| helix.com | 2015 | San Francisco, United States | $435M | – | Genomic database for clinical research is provided. | |
| benchling.com | 2012 | San Francisco, United States | $411.9M | 640 | Cloud-based bioinformatics platform is offered for biotech research. | |
| genuitysci.com | 2013 | Boston, United States | $515M | – | AI-based omics data analysis solutions are provided to researchers. | |
| inpharmatica.co.uk | 1998 | London, United Kingdom | – | 62 | Developer of predictive informatics based platform for drug discovery | |
| bioagelabs.com | 2015 | Vallejo, United States | $293.9M | 43 | Bioinformatics platform is provided for biomarkers and drug discovery. | |
| depixus.com | 2012 | Paris, France | $34.52M | – | Single-molecule genetic and epigenetic sequencing solutions are provided. | |
| genomics.com | 2014 | Oxford, United Kingdom | $115.54M | – | Genomic risk assessment and prevention platform is provided. | |
| sevenbridges.com | 2009 | Cambridge, United States | $113M | 112 | Cloud-based platform to analyze, store, and act on genomic data. |
Detailed competitors of Sequencebase
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
10 companies that operate in the same segment as Sequencebase (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.34 B | USD 301.49 M | 1,372 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 562 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Sequencebase
Complete news archive for Sequencebase
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Sequencebase
Sequencebase was founded in 2006.
Sequencebase is headquartered in Edison, United States. It is registered at Edison, New Jersey, United States.
SequenceBase is an international patent sequence information provider. It develops and markets the SequenceBase Research Portal which is the definitive web-based access point for comprehensive patent sequence searching, featuring streamlined, non-redundant versions of USGENE, GENESEQ, and GENESEQ FASTAlert databases. Databases offered include GENESEQ - which covers all biological sequences patented since 1981 from 52 worldwide patent-issuing authorities including WO, US, EP, JP, DE, IN, KR, and CN and is manually curated and professionally annotated; USGENE which has a thorough coverage of biological sequences from U.S. patents and published patent applications; and WOGENE which claims to have a thorough coverage of biological sequences from international published patent applications. It claims to have a through coverage for all its databases.
Sequencebase's top competitors include Helix, Human Longevity and Benchling.
Sequencebase has 1 investor. Key investors include Clarivate.
Sequencebase operates through Sequencebase Corporation.
Yes. Sequencebase was acquired by Clarivate in September 2019.